par Jalan, Rajiv;Moreau, Richard;Ginès, Pere;Durand, François;Angeli, Paolo;Alessandria, Carlo;Laleman, Wim;Trebicka, Jonel;Samuel, Didier;Zeuzem, Stefan;Gustot, Thierry ;Pavesi, Marco;Gerbes, Alexander L.;Wendon, Julia;Bernardi, Mauro;Arroyo, Vicente;Saliba, Faouzi;Amoros, Alex;Fernandez, Javier;Holland-Fischer, Peter;Sawhney, Rohit;Mookerjee, Rajeshwar;Caraceni, Paolo
Référence Journal of hepatology, 62, 4, page (831-840)
Publication Publié, 2015-04
Référence Journal of hepatology, 62, 4, page (831-840)
Publication Publié, 2015-04
Article révisé par les pairs
Résumé : | Background & Aims Cirrhotic patients with acute decompensation frequently develop acute-on-chronic liver failure (ACLF), which is associated with high mortality rates. Recently, a specific score for these patients has been developed using the CANONIC study database. The aims of this study were to develop and validate the CLIF-C AD score, a specific prognostic score for hospitalised cirrhotic patients with acute decompensation (AD), but without ACLF, and to compare this with the Child-Pugh, MELD, and MELD-Na scores. Methods The derivation set included 1016 CANONIC study patients without ACLF. Proportional hazards models considering liver transplantation as a competing risk were used to identify score parameters. Estimated coefficients were used as relative weights to compute the CLIF-C ADs. External validation was performed in 225 cirrhotic AD patients. CLIF-C ADs was also tested for sequential use. Results Age, serum sodium, white-cell count, creatinine and INR were selected as the best predictors of mortality. The C-index for prediction of mortality was better for CLIF-C ADs compared with Child-Pugh, MELD, and MELD-Nas at predicting 3- and 12-month mortality in the derivation, internal validation and the external dataset. CLIF-C ADs improved in its ability to predict 3-month mortality using data from days 2, 3-7, and 8-15 (C-index: 0.72, 0.75, and 0.77 respectively). Conclusions The new CLIF-C ADs is more accurate than other liver scores in predicting prognosis in hospitalised cirrhotic patients without ACLF. CLIF-C ADs therefore may be used to identify a high-risk cohort for intensive management and a low-risk group that may be discharged early. |